It focuses on ulcerative colitis, CrohnвЂ™s disease, relapsing-remitting multiple sclerosis, and psoriasis. Immunic, Inc is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Based on data from MarketBeat, Immunic currently has an average rating of вЂњBuyвЂќ and a consensus price target of $48.40. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Finally, Wedbush reissued a вЂњbuyвЂќ rating and issued a $61.00 price objective on shares of Immunic in a research report on Friday, October 15th. HC Wainwright cut their price objective on shares of Immunic from $40.00 to $25.00 and set a вЂњbuyвЂќ rating for the company in a research report on Tuesday, September 7th. Zacks Investment Research raised shares of Immunic from a вЂњsellвЂќ rating to a вЂњholdвЂќ rating in a research report on Thursday, September 9th. will post -3.91 earnings per share for the current fiscal year.ДЄ number of equities analysts have recently weighed in on the stock. Sell-side analysts anticipate that Immunic, Inc. During the same quarter last year, the business posted ($0.70) EPS. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, November 4th. The firm has a market capitalization of $226.00 million, a price-to-earnings ratio of -2.35 and a beta of 1.98. The company has a 50 day moving average price of $8.96 and a 200 day moving average price of $10.46. has a one year low of $6.96 and a one year high of $28.21. Shares of IMUX stock opened at $8.61 on Monday. Institutional investors own 35.98% of the companyвЂ™s stock. Northern Trust Corp now owns 165,289 shares of the companyвЂ™s stock worth $2,026,000 after acquiring an additional 65,032 shares during the last quarter. Finally, Northern Trust Corp raised its position in Immunic by 64.9% during the second quarter. now owns 8,509 shares of the companyвЂ™s stock worth $104,000 after acquiring an additional 6,409 shares during the last quarter. raised its position in Immunic by 305.2% during the second quarter. FMR LLC now owns 1,192,722 shares of the companyвЂ™s stock worth $14,623,000 after acquiring an additional 7,380 shares during the last quarter. FMR LLC raised its position in Immunic by 0.6% during the second quarter. Trexquant Investment LP acquired a new position in Immunic during the second quarter worth about $131,000. Bank of New York Mellon Corp now owns 62,825 shares of the companyвЂ™s stock worth $771,000 after acquiring an additional 21,995 shares during the last quarter. Bank of New York Mellon Corp raised its position in Immunic by 53.9% during the second quarter. Other institutional investors and hedge funds have also made changes to their positions in the company. Nuveen Asset Management LLC owned about 0.29% of Immunic worth $919,000 at the end of the most recent reporting period. The fund owned 74,924 shares of the companyвЂ™s stock after acquiring an additional 33,073 shares during the period. (NASDAQ:IMUX) by 79.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. Nuveen Asset Management LLC boosted its holdings in shares of Immunic, Inc.

Hexagon daz studio genesis 2